Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 9;13(12):e071641.
doi: 10.1136/bmjopen-2023-071641.

Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol

Affiliations

Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol

Marie-Louise Zeissler et al. BMJ Open. .

Abstract

Introduction: Parkinson's disease (PD) is a debilitating neurological disorder for which the identification of disease-modifying interventions represents a major unmet need. Diverse trial designs have attempted to mitigate challenges of population heterogeneity, efficacious symptomatic therapy and lack of outcome measures that are objective and sensitive to change in a disease modification setting. It is not clear whether consensus is emerging regarding trial design choices. Here, we report the protocol of a scoping review that will provide a contemporary update on trial design variability for disease-modifying interventions in PD.

Methods and analysis: The Population, Intervention, Comparator, Outcome and Study design (PICOS) framework will be used to structure the review, inform study selection and analysis. The databases MEDLINE, Web of Science, Cochrane and the trial registry ClinicalTrials.gov will be systematically searched to identify published studies and registry entries in English. Two independent reviewers will screen study titles, abstracts and full text for eligibility, with disagreements being resolved through discussion or by a third reviewer where necessary. Data on general study information, eligibility criteria, outcome measures, trial design, retention and statistically significant findings will be extracted into a standardised form. Extracted data will be presented in a descriptive analysis. We will report our findings using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Scoping Review extension.

Ethics and dissemination: This work will provide an overview of variation and emerging trends in trial design choices for disease-modifying trials of PD. Due to the nature of this study, there are no ethical or safety considerations. We plan to publish our findings in a peer-reviewed journal.

Keywords: Parkinson-s disease; clinical trials; systematic review.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow diagram outlining the selection procedure to identify randomised-controlled trials included within the study.

References

    1. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem 2016;139 Suppl 1:318–24. 10.1111/jnc.13691 - DOI - PubMed
    1. Deuschl G, Beghi E, Fazekas F, et al. . The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health 2020;5:e551–67. 10.1016/S2468-2667(20)30190-0 - DOI - PubMed
    1. Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol 2018;16:1239–52. 10.2174/1570159X15666170510143821 - DOI - PMC - PubMed
    1. McGhee DJM, Ritchie CW, Zajicek JP, et al. . A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease. BMC Neurol 2016;16:92. 10.1186/s12883-016-0606-3 - DOI - PMC - PubMed
    1. Investigators NN-P. A randomized, double-blind, futility clinical trial of creatine and Minocycline in early Parkinson disease. Neurology 2006;66:664–71. 10.1212/01.wnl.0000201252.57661.e1 - DOI - PubMed

Publication types